AxoGen, Inc. (0HKD.L)
0HKD.L Stock Price Chart
Explore AxoGen, Inc. interactive price chart. Choose custom timeframes to analyze 0HKD.L price movements and trends.
0HKD.L Company Profile
Discover essential business fundamentals and corporate details for AxoGen, Inc. (0HKD.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Equipment & Services
IPO Date
29 Jan 2018
Employees
451.00
Website
https://www.axogeninc.comCEO
Michael D. Dale
Description
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
0HKD.L Financial Timeline
Browse a chronological timeline of AxoGen, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 23 Feb 2026
Upcoming earnings on 5 Nov 2025
Upcoming earnings on 6 Aug 2025
Revenue estimate is $52.61M.
Earnings released on 8 May 2025
EPS came in at -$0.02 falling short of the estimated $0.01 by -236.99%, while revenue for the quarter reached $48.56M, missing expectations by -8.97%.
Earnings released on 25 Feb 2025
EPS came in at $0.01 falling short of the estimated $0.04 by -73.69%, while revenue for the quarter reached $49.41M, beating expectations by +1.13%.
Earnings released on 7 Nov 2024
EPS came in at $0.07 surpassing the estimated $0.01 by +1.07K%, while revenue for the quarter reached $48.64M, beating expectations by +2.53%.
Earnings released on 8 Aug 2024
EPS came in at -$0.04 surpassing the estimated -$0.06 by +31.33%, while revenue for the quarter reached $47.91M, beating expectations by +10.48%.
Earnings released on 2 May 2024
EPS came in at -$0.15 falling short of the estimated -$0.07 by -125.69%, while revenue for the quarter reached $41.38M, missing expectations by -1.38%.
Earnings released on 5 Mar 2024
EPS came in at -$0.09 falling short of the estimated -$0.07 by -26.51%, while revenue for the quarter reached $42.92M, beating expectations by +4.05%.
Earnings released on 7 Nov 2023
EPS came in at -$0.10 falling short of the estimated -$0.06 by -48.50%, while revenue for the quarter reached $41.27M, beating expectations by +2.03%.
Earnings released on 8 Aug 2023
EPS came in at -$0.16 falling short of the estimated -$0.12 by -28.18%, while revenue for the quarter reached $38.16M, missing expectations by -2.37%.
Earnings released on 9 May 2023
EPS came in at -$0.17 falling short of the estimated -$0.14 by -17.02%, while revenue for the quarter reached $36.66M, beating expectations by +3.67%.
Earnings released on 14 Mar 2023
EPS came in at -$0.13 falling short of the estimated -$0.11 by -13.07%, while revenue for the quarter reached $36.16M, missing expectations by -0.11%.
Earnings released on 30 Sept 2022
EPS came in at -$0.10 surpassing the estimated -$0.13 by +18.83%, while revenue for the quarter reached $36.96M, beating expectations by +2.09%.
Earnings released on 30 Jun 2022
EPS came in at -$0.18 falling short of the estimated -$0.15 by -19.44%, while revenue for the quarter reached $34.45M, beating expectations by +1.87%.
Earnings released on 31 Mar 2022
EPS came in at -$0.27 falling short of the estimated -$0.15 by -81.37%, while revenue for the quarter reached $31.01M, beating expectations by +2.22%.
Dividend declared on 15 Mar 2022
A dividend of $0.29 per share was announced, adjusted to $0.29.
Earnings released on 31 Dec 2021
EPS came in at -$0.13, while revenue for the quarter reached $31.54M.
Earnings released on 30 Sept 2021
EPS came in at -$0.17 falling short of the estimated -$0.13 by -31.00%, while revenue for the quarter reached $31.20M, missing expectations by -1.85%.
Earnings released on 30 Jun 2021
EPS came in at -$0.19, while revenue for the quarter reached $33.58M.
Earnings released on 31 Mar 2021
EPS came in at -$0.16, while revenue for the quarter reached $31.04M.
Earnings released on 31 Dec 2020
EPS came in at -$0.15, while revenue for the quarter reached $32.49M.
Earnings released on 30 Sept 2020
EPS came in at -$0.04, while revenue for the quarter reached $33.43M.
0HKD.L Stock Performance
Access detailed 0HKD.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.